RxSight price target lowered to $70 from $75 at Stifel

Stifel lowered the firm’s price target on RxSight to $70 from $75 and keeps a Buy rating on the shares. The firm surveyed 90 U.S. cataract surgeons, 48 of whom are trained on RxSight’s LAL, and the survey findings lead it to take a more cautious near-to-intermediate-term stance on the stock, the analyst tells investors. The firm maintains a Buy rating as it contends that the longer-term share gain story remains intact, the analyst added.